Neurocrine Biosciences, Inc. research snapshot
NBIX AI stock analysis at the August 2, 2026 data cutoff reads Neurocrine Biosciences as a profitable, growing neuroscience and endocrinology company that delivered a record Q2 2026, raised INGREZZA guidance, and completed the Soleno acquisition, while the stock fell about 10% the day after the report and faces VYKAT XR integration, drug pricing, payer, and pipeline-event risk. At the July 31, 2026 close the price was $166.80 and implied market capitalization was about $16.96 billion, re-verified as $166.80 times 101.65 million shares. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$166.80
Market cap
$16.96 billion
AI score
70 / 100
Rating
Diversifying neuroscience franchise with integration and pricing risk
Trend status
Price pulled back below the 50-day average on July 31, 2026, while holding above the 200-day average, with RSI cooling from overbought to neutral
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Neurocrine commercializes neuroscience and endocrine medicines led by INGREZZA, CRENESSITY, and the newly acquired VYKAT XR, while advancing a mid- to late-stage pipeline including osavampator and direclidine. | High |
| Moat | Regulatory approvals, prescriber relationships, commercial infrastructure, neuroscience and endocrinology development experience, and product-specific clinical evidence support the franchise, while patents, payer access, and competition remain central. | Medium-high |
| Management | CEO Kyle Gano and the team raised INGREZZA guidance, completed the $2.9 billion Soleno acquisition, expanded leadership with a new Chief Business Officer, and are advancing Phase 3 psychiatry programs. Capital allocation should be judged by integration returns and diversification. | Medium |
| Financial trend | Q2 2026 total revenue grew 39% to $959 million with INGREZZA at $716 million, CRENESSITY at $184 million, and VYKAT XR at $54 million. GAAP net income was $144 million and non-GAAP EPS was $2.85. Six-month revenue reached $1.7735 billion with GAAP net income of $342.3 million. | High |
| Valuation | At the $166.80 close, NBIX traded at about 24.5x trailing GAAP EPS, 4.6x book value, 19.5x free cash flow, and 5.0x trailing sales using verified inputs, with a forward PE near 15x against consensus. | Medium-high |
| Technical trend | The July 31, 2026 drop to $166.80 moved price below the 50-day average near $167.35 while it stayed above the 200-day average near $145.91, and RSI cooled from near 74 to 43.85, so the near-term setup is no longer overbought. | Medium |
| Risk level | Risk is medium-high because the thesis faces INGREZZA pricing and IRA exposure into 2027 to 2029, VYKAT XR integration and discontinuation trends, CRENESSITY and pipeline competition, payer decisions, and clinical and regulatory events. | High |
| AI confidence | Reported facts and calculations are well supported, while precise price outcomes cannot be reliably predicted for a pharmaceutical company with event risk. | High data confidence |
| Investment certainty | Medium certainty. Profitability, three commercial products, and no debt help, but durable returns require successful integration, durable INGREZZA pricing, and continued execution after a quarter in which the stock sold off despite a beat and raise. | Medium |
NBIX AI stock forecast
The NBIX AI stock forecast uses a three-year scenario model around the $166.80 July 31 close and TTM GAAP EPS of $6.82, with re-verified valuation math and the consensus view that FY2026 non-GAAP EPS near $9.93 supports a lower forward multiple. The output is conditional rather than a price promise: about $273 in a bullish case, $172 in a base case, and $104 in a bearish case before any possible corporate actions.
$260 to $285
More likely if INGREZZA stays near or above the raised 2026 range of $2.825 billion to $2.875 billion, CRENESSITY keeps expanding, VYKAT XR grows sequentially exiting 2026 and the Soleno integration adds value, late-stage pipeline programs progress, and investors sustain a premium earnings multiple.
$165 to $180
More likely if EPS compounds near 10% annually, INGREZZA growth moderates, CRENESSITY and VYKAT XR contribute gradually, R&D and commercial investment remain elevated, and the market values NBIX near a 19x earnings multiple.
$95 to $115
More likely if price or reimbursement pressure reduces INGREZZA economics, VYKAT XR adoption or discontinuation trends disappoint, CRENESSITY faces stronger competition such as Vertex atumelnant, pipeline studies fail, integration costs rise, or investors compress the multiple toward 14x earnings.
NBIX AI technical analysis
NBIX AI technical analysis turned from overbought to neutral at the August 2, 2026 cutoff. The latest available July 31 close was $166.80, down about 10% for the session and just below the 50-day moving average near $167.35, while the 200-day average near $145.91 remained well below price. RSI fell to 43.85, and the high-volume breakdown on July 31 came after a 52-week high of $186.12 set on July 30.
| Level | Value | Why it matters |
|---|---|---|
| Latest available close | $166.80 | StockAnalysis quote snapshot at the July 31, 2026 close, down 10.08% for the session. Markets were closed by the August 2 research cutoff. |
| Near support | $164.56 | The July 31, 2026 intraday low in the StockAnalysis daily history reference. |
| Secondary support | $154 to $158 | The June 2026 swing-low area, including the $156.31 low on June 18 and $154.84 on June 2. |
| Key support | $145.91 | The 200-day moving average in the latest StockAnalysis statistics reference. |
| Near resistance | $176 to $179 | The early-July consolidation and breakdown zone, including the July 8 and July 9 highs near $178 and $181. |
| Major resistance | $186.12 | The 52-week high set on July 30, 2026, before the post-report selloff. |
| Moving averages | $167.35 and $145.91 | Price closed just below the 50-day average but well above the 200-day average, keeping the intermediate trend intact with a weakened short-term posture. |
| Momentum | RSI 43.85 | RSI cooled from near 74 before the report to a neutral reading after the drop, which reduces the overbought condition rather than confirming a new downtrend by itself. |
| Volume | 20-day average 1.33 million shares | Volume on July 31 was about 4.58 million shares, roughly 3.4 times the 20-day average, showing active selling after the earnings release. |
| Volatility | Beta 0.39 with event risk | The five-year beta was 0.39, but drug-specific news can produce moves that beta does not capture, as the July 31 session showed. |
| Invalidation | Close below $164.56, then $154 to $158 | A sustained break below the July 31 low opens the June range. A close below the 200-day average near $145.91 should trigger a fresh chart and business review. |
NBIX AI trading strategy
The NBIX AI trading strategy is a rules-based framework for a profitable, debt-free pharmaceutical company with concentrated product exposure, a recent acquisition, and clinical-event risk. It is not personal advice and should be checked against live prices, filings, earnings releases, drug data, and individual risk limits.
Watch for NBIX to reclaim and hold the 50-day average near $167.35 and then recover toward the $176 to $179 zone with supportive volume and no deterioration in product-sales or clinical data.
A sustained close below $164.56 weakens the setup. A close below $145.91, the 200-day average, should invalidate the intermediate trend framework and prompt a fundamental review.
If NBIX stabilizes near $164.56 or pulls back toward $154 to $158 without new pricing, payer, clinical, regulatory, or integration problems, compare the move with INGREZZA demand, CRENESSITY and VYKAT XR trends, cash, and guidance.
Do not assume every decline is a buying opportunity. A product-specific setback, trial failure, reimbursement change, or acquisition issue can alter the business case.
Track INGREZZA sales and net price, CRENESSITY reimbursement and uptake, VYKAT XR new starts versus discontinuations, Soleno integration, 2026 guidance, osavampator and direclidine milestones, operating margin, cash, debt, share count, and competitors such as Vertex atumelnant.
Lower confidence if revenue concentration rises, guidance weakens, VYKAT XR fails to grow sequentially, pipeline spend fails to create credible options, or the valuation stays high while earnings quality or cash conversion deteriorates.
Investment research summary
Neurocrine turns neuroscience, endocrine, and immunology research into prescription-medicine revenue by gaining approvals, building specialist demand, supporting payer access, and managing products such as INGREZZA, CRENESSITY, and VYKAT XR through their life cycles.
The moat comes from approved products, clinical evidence, regulatory know-how, specialist relationships, commercial infrastructure, intellectual property, and accumulated development experience. It weakens when competitors, payers, or patent expiry change a medicine economics.
The thesis fails if INGREZZA growth or pricing weakens faster than CRENESSITY and VYKAT XR scale, VYKAT XR discontinuations stay elevated, trials disappoint, regulators or payers restrict access, the Soleno integration underperforms, or R&D spending does not earn adequate returns.
Management raised INGREZZA guidance, completed the $2.9 billion Soleno acquisition with cash and no debt, refreshed leadership, and is funding internal research. The key test is whether these choices create a broader, durable earnings base rather than increasing integration and execution risk.
Neurological, psychiatric, and rare endocrine conditions can benefit from diagnosis, specialist care, and novel therapies, but the industry has concentrated product economics, binary clinical studies, payer scrutiny, and IRA and other policy risk.
NBIX has positive earnings, no debt, and three commercial products, but its valuation still reflects continued growth. Margin of safety improves if VYKAT XR and pipeline assets diversify earnings, and narrows if INGREZZA faces faster price, access, or competitive pressure.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NBIX price | $166.80 at July 31, 2026 close, down 10.08% for the session | StockAnalysis quote snapshot | August 2, 2026 |
| Market capitalization | $16.96 billion, verified as $166.80 x 101.65 million shares with 0.03% deviation | financial_rigor.py market-cap verification and StockAnalysis | August 2, 2026 |
| Q2 2026 total revenue | $959 million, up 39% year over year, with pro-forma total revenue of $998 million | Neurocrine Q2 2026 financial results | August 2, 2026 |
| Q2 2026 product sales | $716 million INGREZZA, $184 million CRENESSITY, and $54 million VYKAT XR from the May 18 closing | Neurocrine Q2 2026 financial results | August 2, 2026 |
| Q2 2026 GAAP and non-GAAP EPS | $1.39 GAAP and $2.85 non-GAAP, with GAAP net income of $144 million | Neurocrine Q2 2026 financial results | August 2, 2026 |
| Six-month 2026 results | Revenue of $1.7735 billion and GAAP net income of $342.3 million, diluted EPS $3.30 | Neurocrine Q2 2026 financial results | August 2, 2026 |
| 2026 INGREZZA net sales guidance | Raised to $2.825 billion to $2.875 billion from $2.7 billion to $2.8 billion | Neurocrine Q2 2026 financial results | August 2, 2026 |
| Cash and marketable securities at June 30, 2026 | About $482 million, down from about $2.543 billion at year-end 2025, with no debt and a $1.0 billion undrawn revolver | Neurocrine Q2 2026 financial results and earnings call | August 2, 2026 |
| FY2025 revenue and GAAP net income | $2.8605 billion, up 21.5%, and $478.6 million | Neurocrine 2025 Form 10-K and StockAnalysis cross-check | August 2, 2026 |
| TTM financials | Revenue $3.374 billion, GAAP net income $705.5 million, EPS $6.82, and free cash flow $870.4 million | StockAnalysis financial statistics | August 2, 2026 |
This NBIX page is an informational research tool, not investment advice or a recommendation to buy or sell. Forecast ranges are scenarios based on available data and may be wrong if financial results, drug pricing, reimbursement, clinical evidence, regulation, competition, acquisition execution, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
